Paediatric Vaccinations
The ideal measure of efficacy, infection rates, is usually not studied as a primary endpoint because this requires large sample sizes. Surrogate measures such as immunogenicity are commonly used instead. Immunogenicity refers to the immune response induced by vaccination. Increased disease activity induced by vaccination and unintentional infections induced by live-attenuated pathogens in vaccines (especially in patients on high-dose immunosuppressive drugs). Another issue of vaccine safety is whether vaccines or their constituents can actually cause autoimmune disease (AID), which will be addressed briefly.
- Two doses of measles mumps rubella at 9 and 15 months of age, and no standalone measles vaccine at 9 months.
- Single dose administration of live attenuated H2 strain hepatitis A vaccine, or two doses of inactivated (killed) hepatitis A vaccine.
Related Conference of Paediatric Vaccinations
August 21-22, 2024
5th International conference on Vaccines, Vaccination and Immunization
Paris, France
September 12-13, 2024
19th International Conference on Allergy and Clinical Immunology
Paris, France
October 24-25, 2024
5th International Conference on Immunology And Immunotherapy
Zurich, Switzerland
Paediatric Vaccinations Conference Speakers
Recommended Sessions
- Immunopathogenesis
- Allergy, Asthma, and Immunology
- Animal & Plant-Derived Vaccines
- Child immunization and Vaccination Viral Immunology
- Clinical and Diagnostic Immunology
- Current research, and future challenges in vaccines
- DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
- Geriatric Immunizations
- Human Vaccines-Infectious & non-Infectious
- Immunoinformatics
- Immunological Disorders
- Immunotoxicology
- Neuroendocrine Immunology
- Onco Immunology
- Paediatric Vaccinations
- Pathology and Immunology
- Psychoneuroimmunology
- Stem cell Immunology
- Vaccine & Immunization
- Vaccines against Drugs
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)